Results 161 to 170 of about 13,011 (272)

Hearing assessment in transfusion dependent beta-thalassemia children on oral iron chelating agent. [PDF]

BMC Pediatr
Mohamed WEI, Tolba MW, Abuelfadl YK, Mohamed Elgendy A, Ali HGA.   +4 more
europepmc   +1 more source

Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy. [PDF]

Ther Adv Endocrinol Metab
Al-Sanabra OM, Abbas MA, Hazàa AA, Hazà WJ.   +3 more
europepmc   +1 more source

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

, 2013
Jae Wook Lee, Sung‐Soo Yoon, Zexiang Shen, Arnold Ganser, Hui‐Chun Hsu, A. El-Ali, Dany Habr, Nicholas G. Martin, John B. Porter   +8 more
openalex   +2 more sources

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes [PDF]

, 2016
Cappellini, MD, Kattamis, A, Porter, JB, Taher, AT, Viprakasit, V   +4 more
core  

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients [PDF]

, 2012
Calvaruso, G, Campisi, S, Capra, M, Caruso, V, Ciancio, A, Cianciulli, P, Cuccia, L, Di Maggio, R, D’Ascola, G, Filosa,A, Gagliardotto, F, Gerardi, C, Lucania, G, Maggio, A, Pantalone, GR, Pitrolo, L, Prossomariti, L, Rigano, P., Rizzo, M, VITRANO, Angela   +19 more
core   +1 more source

The Efficacy and Safety of Deferasirox Monotherapy as a Second-Line Treatment in Transfusion-Dependent Thalassemia with Iron Overload. [PDF]

J Clin Med
Pongamnuaykrit M, Tantiworawit A, Niprapan P, Punnachet T, Hantrakun N, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, Charoenkwan P.   +11 more
europepmc   +1 more source

DEVELOPMENT AND VALIDATION OF DEFERASIROX-RELATED SUBSTANCE METHOD IN SOLID DOSAGE FORMS USING HPLC

Roshni Trivedi, B. N. Suhagia
openalex   +2 more sources

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients [PDF]

, 2010
Keith Tolley, Nick Oliver, Eliana Miranda, Kristen Migliaccio–Walle, Duygu Bozkaya, Q. Li   +5 more
openalex   +1 more source

Impact of iron chelation therapy on mitochondrial function, vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes. [PDF]

Front Immunol
García-Delgado R, Moreno-Carrasco G, Carrasco-Gomariz M, García-Segovia S, Flores RMO, Torres-González J, Gallego-Fuillerat G, López-Villodres JA, Escamilla-Sánchez A.   +8 more
europepmc   +1 more source

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine [PDF]

, 2016
Mohamed Abdel Malik Hassan, Omar Atef Tolba   +1 more
openalex   +1 more source